| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910523748403321 |
|
|
Titolo |
Sport-related sudden cardiac death : causes and prevention / / edited by Pietro Delise and Paolo Zeppilli |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2022] |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (196 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Heart - Diseases - Diagnosis |
Sudden death |
Heart failure |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- 1: Sudden Death in Athletes: Autoptic Findings -- 1.1 Introduction -- 1.2 Aorta and Pulmonary Artery -- 1.3 Coronary Arteries -- 1.4 Myocardium -- 1.5 Valve Disease -- 1.6 Conduction System -- 1.7 Ion Channel Diseases: Sudden Death with Structurally Normal Heart -- 1.8 Role of Autopsy in Case of Sudden Death in Athletes -- 1.9 Toxicological Analysis -- 1.9.1 Sample Preparation -- 1.9.2 General Unknown Screening -- 1.9.3 Interpretation of Results -- References -- 2: Electrocardiographic Changes in the Athlete's Heart -- 2.1 Introduction -- 2.2 The Athlete's ECG: General Considerations -- 2.3 Physiological Changes -- 2.4 Borderline Changes -- 2.5 Abnormal or Pathological Changes -- References -- 3: Benign Arrhythmias and Conduction Defects in Athletes -- 3.1 Sinus Arrhythmia -- 3.1.1 Definition -- 3.1.2 Epidemiology in Sport -- 3.1.3 Current Guidelines -- 3.2 Sinus Bradycardia -- 3.2.1 Definition -- 3.2.2 Epidemiology in Sport -- 3.2.3 Current Guidelines -- 3.3 Right Bundle Branch Block -- 3.3.1 Definition -- 3.3.2 Epidemiology in Sport -- 3.3.3 Current Guidelines -- 3.4 Left Bundle Branch Block -- 3.4.1 Definition -- 3.4.2 Epidemiology in Sport -- 3.4.3 Current Guidelines -- 3.5 Atrio-Ventricular Blocks -- 3.5.1 Definition -- 3.5.2 Epidemiology in Sport -- 3.5.3 Current Guidelines -- 3.6 Premature Ventricular Beats -- |
|
|
|
|
|
|
|
|
|
3.6.1 Definition -- 3.6.2 Epidemiology in Athletes -- 3.6.3 Current Guidelines -- References -- 4: Hypertrophic Cardiomyopathy and Left Ventricular Non-Compaction -- 4.1 Text -- 4.2 Risk Stratification in Athletes with Hypertrophic Cardiomyopathy -- 4.3 Left Ventricular Non-Compaction Cardiomyopathy -- References -- 5: Arrhythmogenic Cardiomyopathy -- 5.1 Introduction -- 5.2 Definition and Pathological Findings. |
5.3 Pathophysiology of Ventricular Arrhythmias in AC -- 5.4 AC and SD in Athletes -- 5.5 Early Identification at Pre-participation Screening -- References -- 6: Acute and Chronic Myocarditis -- 6.1 Clinical and Electrocardiographic Findings -- 6.2 Additional Instrumental Findings (Imaging Techniques and Endomyocardial Biopsy) -- 6.3 Athletes with Fever: What to Suggest to Sports Physicians -- 6.4 Long-Term Outcome of Myocarditis: Chronic Persistence of Inflammation and Residual Fibrosis -- 6.5 Clinical and Prognostic Significance of Chronically Residual Fibrosis -- 6.6 When ECG Suggests the Presence of Fibrosis -- 6.7 Sport Eligibility After Myocarditis -- References -- 7: Congenital and Acquired Anomalies of Coronary Arteries -- 7.1 Introduction -- 7.2 Congenital Anomalies -- 7.3 Anomalous Origin of Coronary Arteries -- 7.4 Myocardial Bridge -- 7.5 Coronary Fistulae -- 7.6 Acquired Anomalies -- 7.6.1 Coronary Atherosclerosis -- 7.6.2 Kawasaki's Disease -- 7.6.3 Cocaine-Induced Coronary Disease -- References -- 8: Interpretation and Diagnostic Workup of Premature Ventricular Beats -- 8.1 Introduction -- 8.2 The Concept of "Common" and "Uncommon" PVBs -- 8.3 Pathological Substrates in Athletes with PVBs -- 8.4 Recent Evidence on Ventricular Ectopy in Athletes -- 8.5 Diagnostic Workup of Premature Ventricular Beats in Athletes -- 8.6 Conclusions -- References -- 9: Fear of Sudden Death During Sport Activity and the Long QT Syndrome -- 9.1 Foreword -- 9.2 Introduction -- 9.3 Key Features of LQTS -- 9.4 Problems and Errors -- 9.5 What Should Not Happen -- 9.6 A Dangerous Trap -- 9.7 Our Approach and Our Recommendations -- References -- 10: Short QT Syndrome -- 10.1 Background -- 10.2 ECG Diagnosis of Short QT Syndrome and Differential Diagnosis -- 10.2.1 QT and QTc Interval -- 10.2.2 QT/HR Relationship. |
10.2.3 Other ECG Features -- 10.2.3.1 T Wave Morphology and J-Tpeak Interval -- 10.2.3.2 PQ Segment Depression -- 10.2.3.3 Early Repolarisation Pattern -- 10.3 Genetics and Molecular Basis -- 10.4 Clinical Manifestations and Mechanisms of Arrhythmias -- 10.5 Management of SQTS Patients -- 10.6 Sports Recommendations -- References -- 11: Brugada ECG Pattern and Brugada Syndrome -- 11.1 Brugada Type 1 ECG and Prognosis -- 11.2 Genetic Basis of Brugada Syndrome -- 11.3 Risk Stratification in Individuals with Brugada Type 1 ECG Pattern -- 11.4 Brugada ECG Pattern in Athletes -- 11.5 Brugada Syndrome and Risk of SD Related to Sport Activity -- 11.6 Sports Eligibility in Subjects with Brugada Syndrome and a BrS Type 1 ECG -- 11.7 Drug-Induced Br Type 1 ECG: Indications and Sports Eligibility -- References -- 12: Early Repolarization Syndrome -- 12.1 Benign Left ER and ERS Differential Diagnosis -- 12.2 Early Repolarization Syndrome Causes and Complications -- 12.3 ERS ECG Pattern and Risk of SD Related to Sport Activity -- 12.3.1 Sports Eligibility in Subjects with Definite or Suspected ERS -- References -- 13: Catecholaminergic Polymorphic Ventricular Tachycardia -- 13.1 Introduction -- 13.2 Epidemiology -- 13.3 Genetic Background -- 13.3.1 Cardiac Ryanodine Receptor (RYR2) -- 13.3.2 Cardiac Calsequestrin (CASQ2) -- 13.4 Other Genes Associated with CPVT -- 13.4.1 Triadin (TRDN) -- 13.4.2 Calmodulin (CALM) -- 13.4.3 Trans-2,3-Enoyl-CoA Reductase-Like (TECRL) -- 13.5 Pathophysiology -- 13.5.1 |
|
|
|
|
|
|
|
|
Excitation-Contraction Coupling and Calcium-Induced Calcium Release (CICR) -- 13.6 Molecular Pathophysiology -- 13.6.1 RYR2 Mutations -- 13.6.2 CASQ2 Mutations -- 13.6.3 TRDN Mutations -- 13.7 Arrhythmogenic Mechanisms -- 13.8 Clinical Manifestations and Diagnosis -- 13.9 Differential Diagnosis -- 13.10 Principles of Management. |
13.11 Lifestyle -- 13.12 Pharmacological Treatment -- 13.12.1 Beta-Blockers -- 13.12.2 Flecainide -- 13.13 Left Cardiac Sympathetic Denervation -- 13.14 Implantable Cardioverter Defibrillator -- 13.15 Future Therapies -- References -- 14: Sport Activity in Subjects with Implantable Defibrillator -- 14.1 Background -- 14.2 Epidemiology -- 14.3 Cultural Aspects and Published Experiences -- 14.4 Actual Recommendations (Tables 14.1, 14.2, and 14.3) -- 14.5 Subcutaneous ICD -- 14.6 Discussion and Perspectives -- References. |
|
|
|
|
|
| |